Open Access. Powered by Scholars. Published by Universities.®
- Publication
Articles 1 - 2 of 2
Full-Text Articles in Chemicals and Drugs
New Antibiotics In Clinical Trials For Clostridium Difficile, Eric Slayton, Abigail Hay Pharmd, Charles K. Babcock, Timothy E. Long Phd
New Antibiotics In Clinical Trials For Clostridium Difficile, Eric Slayton, Abigail Hay Pharmd, Charles K. Babcock, Timothy E. Long Phd
Timothy Long
This article reviews the preclinical and clinical studies of cadazolid, LFF571, ridinilazole, and surotomycin. The advantages that these antibiotics may have in the treatment of CDI is compared with current therapies metronidazole, vancomycin, and fidaxomicin. Expert commentary: The antibiotics examined have the potential to improve rates of CDI treatment without recurrence. We anticipate that one or more of these medications will be approved within five years.
New Antibiotics In Clinical Trials For Clostridium Difficile, Eric Slayton, Abigail Hay Pharmd, Charles K. Babcock, Timothy E. Long Phd
New Antibiotics In Clinical Trials For Clostridium Difficile, Eric Slayton, Abigail Hay Pharmd, Charles K. Babcock, Timothy E. Long Phd
Charles Babcock
This article reviews the preclinical and clinical studies of cadazolid, LFF571, ridinilazole, and surotomycin. The advantages that these antibiotics may have in the treatment of CDI is compared with current therapies metronidazole, vancomycin, and fidaxomicin. Expert commentary: The antibiotics examined have the potential to improve rates of CDI treatment without recurrence. We anticipate that one or more of these medications will be approved within five years.